207 related articles for article (PubMed ID: 22927482)
1. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Moroney J; Fu S; Moulder S; Falchook G; Helgason T; Levenback C; Hong D; Naing A; Wheler J; Kurzrock R
Clin Cancer Res; 2012 Oct; 18(20):5796-805. PubMed ID: 22927482
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
Moroney JW; Schlumbrecht MP; Helgason T; Coleman RL; Moulder S; Naing A; Bodurka DC; Janku F; Hong DS; Kurzrock R
Clin Cancer Res; 2011 Nov; 17(21):6840-6. PubMed ID: 21890452
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Moulder S; Helgason T; Janku F; Wheler J; Moroney J; Booser D; Albarracin C; Morrow PK; Atkins J; Koenig K; Gilcrease M; Kurzrock R
Ann Oncol; 2015 Jul; 26(7):1346-52. PubMed ID: 25878190
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Basho RK; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Herbrich SM; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Ibrahim NK; Murray JL; Koenig KB; Hong D; Subbiah V; Kurzrock R; Janku F; Moulder SL
JAMA Oncol; 2017 Apr; 3(4):509-515. PubMed ID: 27893038
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
[TBL] [Abstract][Full Text] [Related]
6. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT.
Boers-Sonderen MJ; de Geus-Oei LF; Desar IM; van der Graaf WT; Oyen WJ; Ottevanger PB; van Herpen CM
Target Oncol; 2014 Dec; 9(4):339-47. PubMed ID: 24577626
[TBL] [Abstract][Full Text] [Related]
7. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
Piha-Paul SA; Wheler JJ; Fu S; Levenback C; Lu K; Falchook GS; Naing A; Hong DS; Tsimberidou AM; Kurzrock R
Oncotarget; 2014 Apr; 5(7):1846-55. PubMed ID: 24742900
[TBL] [Abstract][Full Text] [Related]
8. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.
Merchan JR; Qin R; Pitot H; Picus J; Liu G; Fitch T; Maples WJ; Flynn PJ; Fruth BF; Erlichman C
Cancer Chemother Pharmacol; 2015 Mar; 75(3):485-93. PubMed ID: 25556030
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
Altomare I; Bendell JC; Bullock KE; Uronis HE; Morse MA; Hsu SD; Zafar SY; Blobe GC; Pang H; Honeycutt W; Sutton L; Hurwitz HI
Oncologist; 2011; 16(8):1131-7. PubMed ID: 21795432
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.
Ranieri G; Ferrari C; Di Palo A; Marech I; Porcelli M; Falagario G; Ritrovato F; Ramunni L; Fanelli M; Rubini G; Gadaleta CD
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28684680
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.
Keefe SM; Hoffman-Censits J; Cohen RB; Mamtani R; Heitjan D; Eliasof S; Nixon A; Turnbull B; Garmey EG; Gunnarsson O; Waliki M; Ciconte J; Jayaraman L; Senderowicz A; Tellez AB; Hennessy M; Piscitelli A; Vaughn D; Smith A; Haas NB
Ann Oncol; 2016 Aug; 27(8):1579-85. PubMed ID: 27457310
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.
Knox JJ; Qin R; Strosberg JR; Tan B; Kaubisch A; El-Khoueiry AB; Bekaii-Saab TS; Rousey SR; Chen HX; Erlichman C
Invest New Drugs; 2015 Feb; 33(1):241-6. PubMed ID: 25318437
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
Teoh D; Secord AA
Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
[TBL] [Abstract][Full Text] [Related]
17. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
18. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.
Hobday TJ; Qin R; Reidy-Lagunes D; Moore MJ; Strosberg J; Kaubisch A; Shah M; Kindler HL; Lenz HJ; Chen H; Erlichman C
J Clin Oncol; 2015 May; 33(14):1551-6. PubMed ID: 25488966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
